Skip to content
value.today
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc.

🇺🇸 Bethesda, Maryland, USABiotechnologyFounded 2020
Total raised
$10 M
1 round on record
Latest round
$10 M
Jul 2020
First round on record
Jul 2020
Today
Went public
See the company page

Gain Therapeutics, Inc. is listed today as Gain Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Gain Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$10 MNo. 1$10 to $50 million

Gain Therapeutics, Inc.: Raise no. 1, Jul 2020

Investors in this round

48 investors had bought by the notice of Jul 30, 2020: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric I. Richman · Executive Officer, Director
  • Jeffrey I. Riley · Director
  • Khalid I. Islam · Director
  • Lorenzo I. Leoni · Director · Proceeds may be used to pay for overhead and expenses which may include salaries.
  • Marianne I. Bjordal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Tribal Capital Markets, LLC (CRD 38901) · Red Bank, New JerseySold in AL, AZ, CA, FL, IN, MD, NJ, NY, OH, PR, TX

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay for overhead and expenses which may include salaries.”

Signed by Eric I. Richman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 30, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Gain Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2020

That is all the official record says: Gain Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Gain Therapeutics, Inc. are on record.

Investors#

No investor of Gain Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 48 investors.

Largest shareholders today

Institutions holding Gain Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gain Therapeutics, Inc.
NameRoleNamed in
Eric I. RichmanExecutive officerJul 2020
Eric I. RichmanDirectorJul 2020
Jeffrey I. RileyDirectorJul 2020
Khalid I. IslamDirectorJul 2020
Lorenzo I. LeoniProceeds may be used to pay for overhead and expenses which may include salaries.Jul 2020
Marianne I. BjordalDirectorJul 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.